Chordia Therapeutics (190A) · InitiativeFirst statedLatest Presentation materials on financial results (2026-10-15): "Advanced"
Considering domestic in-house sales of CTX-712 or joint development with a pharmaceutical company
First written in FY2024. 1 of 2 entries say "Advanced", first in 2026-10-15. Latest entry: 2026-10-15.
2entries
3years
1from disclosures
How it moved
Same theme, other companies
Evaluating commercialization structure options for CTX-712 in JapanA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-10-15AdvancedPresentation materials on financial results
「国内：自社での製造・販売 海外：ライセンスアウト」
rogocekibの地域別の事業化方針として、国内は自社での製造・販売、海外はライセンスアウトという選択肢が具体的に示された。 - FY2024First statedAnnual report
「At the same time, we are considering commercializing the product in Japan primarily through our own operations without partnering with a pharmaceutical company, and have entered into a business partnership with Medipal Holdings Co., Ltd. and a basic agreement on collaboration with Shionogi Pharma Co., Ltd.」
For commercialization in Japan, both a sales structure centered on the company's own operations and a partnership with a pharmaceutical company are being considered as options. The parties are at the basic-agreement stage, and the policy of selling directly in Japan has not been finalized.